News | August 19, 2007

PENN Medicine Creates GPS for the Body

August 20, 2007 - Operating under the same tracking principles as a global positioning system, the Calypso 4D Localization System, a GPS for the Body, is now available from PENN Medicine’s Department of Radiation Oncology, offering cancer patient's real-time tracking of the prostate gland during radiation treatment with IMRT or intensity-modulated radiation therapy.

The Calypso 4D Localization System works just like a GPS tracking system but for the prostate. It allows for continuous monitoring of the prostate gland during treatment. Three miniature electromagnetic sensorsveach, no bigger than a grain of rice, are implanted into the prostate during a brief outpatient procedure. Called Beacon transponders, these micro mini transmitters monitor the position and motion of the prostate in real-time, continuously sending signals to a receiver in the radiation treatment room. Before each treatment, the Calypso seeks out the "beacons" and helps the technologist to re-align the treatment plan. This system is reportedly the only one to offer "real time tracking" which helps improve the accuracy of delivering radiation.

As of now, the Calypso System is only FDA approved for prostate cancer and the first patient was treated this May.

For more information:

Related Content

Hypofractionated Radiation Provides Same Prostate Cancer Outcomes as Conventional Radiation
News | Intensity Modulated Radiation Therapy (IMRT) | October 31, 2018
An analysis led by researchers at Philadelphia’s Fox Chase Cancer Center found treating localized prostate cancer with...
IBA Completes Installation of Two Proteus One Proton Therapy Systems in Japan
News | Proton Therapy | July 30, 2018
IBA (Ion Beam Applications S.A.) announced that they completed the first two installations of the Proteus One proton...
​ITN Celebrates World Cancer Day 2018
News | Radiation Oncology | February 01, 2018
World Cancer Day takes place annually on Feb.
UZ Leuven Treats First European Patient on Varian Halcyon Cancer Treatment System
News | Intensity Modulated Radiation Therapy (IMRT) | October 25, 2017
Varian recently announced an 80-year-old male with head and neck cancer became the first patient in Europe to be...
Varian Receives FDA 510k Clearance for Halcyon Treatment System
Technology | Intensity Modulated Radiation Therapy (IMRT) | July 05, 2017
Varian Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Halcyon system,...
First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System
News | Image Guided Radiation Therapy (IGRT) | July 03, 2017
Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS),...
IUCT Oncopole Installs First Radixact Radiotherapy System in France
News | Intensity Modulated Radiation Therapy (IMRT) | June 20, 2017
Accuray Inc. announced that the University Cancer Institute of Toulouse Oncopole (IUCT Oncopole) in Toulouse, France,...
cervical and endometrial cancer, IMRT, intensity modulated radiation therapy, side effects, ASTRO 2016 study
News | Intensity Modulated Radiation Therapy (IMRT) | September 29, 2016
Patients with cervical and endometrial cancer have fewer gastrointestinal and genitourinary side effects and experience...